Ferric Carboxymaltose: Drug for Iron Deficiency in Patients with Heart Failure
Article Sidebar
Main Article Content
Abstract
Ferric carboxymaltose is a new injectable iron registered in Thailand since 2020. It is indicated for the treatment of iron deficiency anemia. The recommended dose is 15 mg/kg with maximum dose not exceeding to 1000 mg within 15-30 minutes. Based on efficacy studies of ferric carboxymaltose in HFrEF (heart failure with reduced ejection fraction) patients with iron deficiency (a ferritin level of less than 100 ng/mL or a ferritin level of 100-299 ng/mL with a TSAT or transferrin saturation of less than 20%), the drug was found to reduce the severity of heart failure as assessed from NYHA (New York Heart Association) functional class, increases exercise capacity, reduce the rate of hospitalization and increase quality of life. The 2016 European Society of Cardiology (ESC) guidelines recommend the use of ferric carboxymaltose (class of recommendation IIa, level of evidence A) for this group of patients. In terms of safety, severe adverse reactions were acute allergic reactions (anaphylactoid/anaphylactic reactions) in 0.3-0.8% of patients. The most common adverse reactions were nausea, high blood pressure and low blood phosphate. This article provides information on ferric carboxymaltose in terms of general information, dosage, administration, efficacy and adverse drug reactions, to guide the use this drug.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
ผลการวิจัยและความคิดเห็นที่ปรากฏในบทความถือเป็นความคิดเห็นและอยู่ในความรับผิดชอบของผู้นิพนธ์ มิใช่ความเห็นหรือความรับผิดชอบของกองบรรณาธิการ หรือคณะเภสัชศาสตร์ มหาวิทยาลัยสงขลานครินทร์ ทั้งนี้ไม่รวมความผิดพลาดอันเกิดจากการพิมพ์ บทความที่ได้รับการเผยแพร่โดยวารสารเภสัชกรรมไทยถือเป็นสิทธิ์ของวารสารฯ
References
Loncar G, Obradovic D, Thiele H, von Haehling S, Lainscak M. Iron deficiency in heart failure [online]. 2021 [cited Jul 20, 2021]. Available from: www.on linelibrary.wiley.com/doi/full/10.1002/ehf2.13265.
von Haehling S, Ebner N, Evertz R, Ponikowski P, Anker SD. Iron deficiency in heart failure: An overview. JACC: Heart Fail 2019; 7: 36-46.
McDonagh T, Damy T, Doehner W, Lam CSP, Sindone A, van der Meer P, et al. Screening, diagnosis and treatment of iron deficiency in chronic heart failure: putting the 2016 European Society of Cardiology Heart Failure guidelines into clinical practice. Eur J Heart Fail 2018;20:1664-72.
Anand IS, Gupta PJC. Anemia and iron deficiency in heart failure: current concepts and emerging therapies. Circulation 2018; 138: 80-98.
Bhandari S, Pereira DI, Chappell HF, Drakesmith HJP. Intravenous irons: from basic science to clinical practice. Pharmaceuticals (Basel) 2018; 11: 82.
Rockey DC. Treatment of iron deficiency. Gastroen terology 2006; 130: 1367-8.
Lewis GD, Malhotra R, Hernandez AF, McNulty SE, Smith A, Felker GM, et al. Effect of oral iron repletion on exercise capacity in patients with heart failure with reduced ejection fraction and iron deficiency: the IRONOUT HF randomized clinical trial. JAMA 2017; 317: 1958-66.
Beck-da-Silva L, Piardi D, Soder S, Rohde LE, Pereira-Barretto AC, de Albuquerque D, et al. IRON-HF study: a randomized trial to assess the effects of iron in heart failure patients with anemia. Int J Cardiol 2013; 168: 3439-42.
Okonko DO, Grzeslo A, Witkowski T, Mandal AK, Slater RM, Roughton M, et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency: FERRIC-HF: a randomized, controlled, observer-blinded trial. J Am Coll Cardiol 2008;51:103-12.
Zuellig Pharma. ferric carboxymaltose (Ferinject). Full prescribing information Zuellig Pharma Ltd; 2020.
Ding Y, Zhu X, Li X, Zhang H, Wu M, Liu J, et al. Pharmacokinetic, pharmacodynamic, and safety profiles of ferric carboxymaltose in Chinese patients with iron-deficiency anemia. Clin Ther 2020;42:276-85.
Ikuta K, Shimura A, Terauchi M, Yoshii K, Kawabata YJIjoh. Pharmacokinetics, pharmacodynamics, safety, and tolerability of intravenous ferric carboxy maltose: a dose-escalation study in Japanese volunteers with iron-deficiency anemia. Int J Hematol 2018;107:519-27.
Scott LJ. Ferric carboxymaltose: A review in iron deficiency. Drugs 2018;78:479-93.
Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, et al. Ferric carboxy maltose in patients with heart failure and iron deficiency. N Engl J Med 2009;361:2436-48.
McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012; 33: 1787-847.
Ponikowski P, van Veldhuisen DJ, Comin‐Colet J, Ertl G, Komajda M, Mareev V, et al. Beneficial effects of long‐term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J 2015 ; 36: 657–668.
van Veldhuisen DJ, Ponikowski P, van der Meer P, Metra M, Böhm M, Doletsky A, et al. Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency. Circulation 2017; 136: 1374-83.
Ponikowski P, Kirwan B-A, Anker SD, McDonagh T, Dorobantu M, Drozdz J, et al. Ferric carboxymal- tose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomis- ed, controlled trial. Lancet 2020; 396: 1895-904.
Onken JE, Bregman DB, Harrington RA, Morris D, Buerkert J, Hamerski D, et al. Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial. Nephrol Dial Transplant. 2014;29:833-42.
Glaspy JA, Lim-Watson MZ, Libre MA, Karkare SS, Hadker N, Bajic-Lucas A, et al. Hypophosphatemia associated with Intravenous iron therapies for iron deficiency anemia: A systematic literature review. Ther Clin Risk Manag 2020;16:245-59.
Macdougall IC, Bock AH, Carrera F, Eckardt KU, Gaillard C, Van Wyck D, et al. FIND-CKD: a randomized trial of intravenous ferric carboxy maltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrol Dial Transplant 2014; 29: 2075-84.
Keating GM. Ferric carboxymaltose: a review of its use in iron deficiency. Drugs 2015;75:101-27.
Breymann C, Gliga F, Bejenariu C, Strizhova NJ, Obstetrics. Comparative efficacy and safety of intra venous ferric carboxymaltose in the treatment of postpartum iron deficiency anemia. Int J Gynaecol Obstet 2008; 101: 67-73.